Clinical pediatrics · 2025
Effective Pseudomonas aeruginosa Eradication in Cystic Fibrosis: Multicenter Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guliyeva Aynur, Yilmaz Yegit Cansu, Yanaz Muruvvet, Kalyoncu Mine, Selçuk Balcı Merve, Karabulut Seyda, Ergenekon Almala Pınar, Tastan Gamze, Uzunoglu Burcu, Arslan Hüseyin, Yazan Hakan, Bilgin Gülay Bas, Köstereli Ebru, Kılınc Sakallı Ayse Ayzıt, Cakır Erkan, Girit Saniye, Uyan Zeynep Seda, Gokdemir Yasemin, Erdem Eralp Ela, Karakoc Fazilet, Karadag Bulent
Аннотация
BACKGROUND: Pseudomonas aeruginosa (PA) eradication is crucial in cystic fibrosis (CF) management. At our center, the success rate was 21.6%, prompting a revised eradication protocol to evaluate a new regimen.
METHODS: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.
RESULTS: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).
CONCLUSION: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.
METHODS: Cystic fibrosis patients with first-time PA detection were included. Nonmucoid PA cases received oral ciprofloxacin (3 weeks) and inhaled tobramycin (1 month). For mucoid PA or failed eradication, ciprofloxacin (3 weeks) and extended nebulized therapy (3 months, alternating tobramycin/colistin) were used. Intravenous antibiotics were given to unwell patients.
RESULTS: Among 109 CF patients (median age: 6 years), 79 (72.5%) achieved successful eradication. Oral ciprofloxacin and tobramycin inhalation were used in 66 patients (60.6%), extended nebulized therapy in 26 (23.8%), and intravenous antibiotics in 17(15.6%).
CONCLUSION: The revised protocol achieved a high PA eradication rate in CF patients. Adapting treatment regimens based on PA characteristics and patient condition can optimize outcomes and improve CF management.